Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obinutuzumab, Ibrutinib, and Venetoclax in Previously Untreated Follicular Lymphoma
NCT04450173Phase 2Active, not recruiting
- Sponsor
- University of California, Davis
- Start
- Feb 2021
- Primary completion
- Apr 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of obinutuzumab, ibrutinib and venetoclax in follicular lymphoma (FL), sponsored by University of California, Davis. Primary endpoint: Complete Response Rate at 12 months. Started Feb 2021; status: active, not recruiting.
02
Drugs
obinutuzumabibrutinibvenetoclax
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT04450173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04450173.